Low-Dose Methotrexate for the Prevention of Atherosclerotic Events

BACKGROUND: Inflammation is causally related to atherothrombosis. Treatment with canakinumab, a monoclonal antibody that inhibits inflammation by neutralizing interleukin-1β, resulted in a lower rate of cardiovascular events than placebo in a previous randomized trial. We sought to determine whether...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :N Engl J Med
Главные авторы: Ridker, Paul M, Everett, Brendan M., Pradhan, Aruna, MacFadyen, Jean G., Solomon, Daniel H., Zaharris, Elaine, Mam, Virak, Hasan, Ahmed, Rosenberg, Yves, Iturriaga, Erin, Gupta, Milan, Tsigoulis, Michelle, Verma, Subodh, Clearfield, Michael, Libby, Peter, Goldhaber, Samuel Z., Seagle, Roger, Ofori, Cyril, Saklayen, Mohammad, Butman, Samuel, Singh, Narendra, May, Michel Le, Bertrand, Olivier, Johnston, James, Paynter, Nina P., Glynn, Robert J.
Формат: Artigo
Язык:Inglês
Опубликовано: 2018
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC6587584/
https://ncbi.nlm.nih.gov/pubmed/30415610
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1809798
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы